Risk‑Stratified Management of Myelodysplastic Syndrome

Risk Stratification

The NCCN guidelines state that treatment decisions for myelodysplastic syndrome (MDS) must be based on the Revised International Prognostic Scoring System (IPSS‑R), which separates patients into lower‑risk (very low, low, intermediate) and higher‑risk (intermediate, high, very high) categories, each with distinct therapeutic goals. 1
According to the NCCN, the IPSS‑R incorporates peripheral‑blood cytopenias, bone‑marrow blast percentage, and cytogenetic abnormalities to predict overall survival and the risk of transformation to acute myeloid leukemia. 2
Patients classified as IPSS‑R intermediate may be managed as either lower‑ or higher‑risk depending on age, performance status, serum ferritin, lactate dehydrogenase, and early response to therapy. 1

Lower‑Risk MDS – Primary Goal: Symptom Control and Quality of Life

The NCCN recommends that the main objective for lower‑risk MDS is to treat symptomatic cytopenias (especially anemia), improve quality of life, and reduce transfusion requirements rather than to alter disease biology. 3
First‑line anemia therapy: Erythropoiesis‑stimulating agents (recombinant erythropoietin or darbepoetin) ± granulocyte‑colony stimulating factor are advised as initial treatment for symptomatic anemia. 4
ESAs produce erythroid responses in 40–60 % of patients when baseline serum erythropoietin is low (<200–500 U/L) and transfusion needs are modest (<2 units/month). 4
Predictors of a favorable ESA response include low baseline serum erythropoietin, low marrow blast percentage, and minimal prior transfusions. 4
Supportive transfusion care: Red blood cell transfusions should be given to maintain hemoglobin > 8–10 g/dL based on symptoms. 4
Platelet transfusions are indicated for active bleeding or severe thrombocytopenia. 5
Granulocyte‑colony stimulating factor is recommended for recurrent infections in neutropenic patients. 5
Lenalidomide for isolated del(5q): Before initiating lenalidomide in patients with isolated del(5q), testing for TP53 mutations is advised because such mutations predict reduced response or early relapse. 1

Higher‑Risk MDS – Primary Goal: Disease Modification and Survival

For higher‑risk disease, the NCCN emphasizes delaying progression to AML, achieving complete or partial remission, and prolonging overall survival rather than merely correcting cytopenias. 3

Hypomethylating Agents (HMAs) – First‑Line

Azacitidine (75 mg/m² subcutaneously for 7 consecutive days every 28 days) is the reference first‑line therapy for higher‑risk patients who are not immediate candidates for allogeneic stem‑cell transplantation. (Class I recommendation, NCCN) 3
A minimum of six treatment cycles should be completed before response assessment, as most responses occur after several courses. (Class I, NCCN) 3
In a pivotal trial, azacitidine improved overall survival by up to 74 % compared with conventional care, with complete response rates of 15–20 %. (Level A evidence) 3
An alternative “5‑2‑2” dosing schedule (5 days on, 2 days off, 2 days on) is acceptable for logistical reasons. (Class IIa, NCCN) 3

Allogeneic Stem‑Cell Transplantation (allo‑SCT)

The NCCN identifies allo‑SCT as the only potentially curative option and recommends evaluating all higher‑risk patients at diagnosis for transplant eligibility if they are ≤ 65–70 years old (or fit > 70 years) and have an HLA‑identical sibling or matched unrelated donor. (Class I, NCCN) 6
Patients < 55 years without significant comorbidities should receive myeloablative conditioning, whereas older or less‑fit patients should receive reduced‑intensity conditioning. (Class IIa, NCCN) 6
Administering HMAs for 2–6 cycles before transplant can lower blast burden and provide time to secure a donor. (Class IIb, NCCN) 3

Intensive AML‑Like Chemotherapy – Limited Indication

Intensive regimens (e.g., cytarabine + idarubicin or fludarabine) are reserved for fit patients < 70 years with favorable cytogenetics (especially normal karyotype), > 10 % marrow blasts, and when used as a bridge to allo‑SCT. (Class IIb, NCCN) 6
Patients with unfavorable cytogenetics derive few complete remissions and experience shorter remission durations with intensive chemotherapy. (Level B evidence) 6
A randomized trial suggested that azacitidine may confer superior survival compared with intensive chemotherapy, although the study was underpowered. (Level B evidence) 6

Low‑Dose Cytarabine – Inferior Alternative

Low‑dose cytarabine (20 mg/m²/day for 14–21 days every 4 weeks) is significantly less effective than azacitidine and should be used only when HMAs are unavailable, preferably in patients with normal karyotype. (Class III, NCCN) 6

Management After HMA Failure

Patients with higher‑risk MDS who are refractory to HMAs have a median survival of < 6 months; enrollment in clinical trials or proceeding directly to allo‑SCT (if eligible) is recommended. (Class I, NCCN) 3
Retreatment with intensive chemotherapy or low‑dose cytarabine after HMA failure yields dismal outcomes and is not recommended outside of trial settings. (Level C evidence) 6

Special Populations

Very frail higher‑risk patients should receive supportive care only (transfusions, antibiotics, growth factors) rather than disease‑modifying therapy. (Class III, NCCN) 3
Therapy‑related MDS is associated with a high frequency of poor‑risk cytogenetics and should be managed as higher‑risk disease irrespective of the IPSS‑R score. (Class I, NCCN) 1

Monitoring and Response Assessment

Treatment effectiveness should be evaluated using the International Working Group (IWG) 2006 response criteria, which define complete remission, partial remission, and hematologic improvement. (Class I, NCCN) 2

Critical Pitfalls (NCCN Recommendations)

Do not discontinue azacitidine before completing six cycles unless clear disease progression is documented. (Class I, NCCN) 3
Do not employ intensive AML‑like chemotherapy in patients with unfavorable cytogenetics outside of clinical trials, as outcomes are poor. (Class III, NCCN) 6
Do not postpone allo‑SCT evaluation in eligible higher‑risk patients; transplant assessment should occur at diagnosis. (Class I, NCCN) 6

Myelodysplastic Syndrome (MDS) Treatment Guidelines

Introduction to MDS

Myelodysplastic Syndrome (MDS) comprises clonal hematopoietic malignancies causing bone marrow dysplasia with peripheral cytopenias and increased risk of acute myeloid leukemia (AML) transformation, with a median age at diagnosis of approximately 70 years 7, 8.

Risk Stratification

The International Prognostic Scoring System-Revised (IPSS-R) is essential for determining all treatment decisions, evaluating peripheral blood cytopenias severity, bone marrow blast percentage, and cytogenetic abnormalities 7, 9.

Treatment Objectives

In lower-risk MDS, the primary goal is treating cytopenias, improving quality of life, and reducing transfusion burden, with approximately half of elderly lower-risk patients dying from causes unrelated to MDS or AML 7, 8, 10, 11.
In higher-risk MDS, treatment goals shift to altering the natural history of disease by delaying AML progression and prolonging overall survival, with primary treatment objectives including achieving complete remission or partial remission and prolonging progression-free survival and overall survival 12, 9.

Treatment Approach

For lower-risk MDS, first-line treatment includes erythropoiesis-stimulating agents (ESAs) such as recombinant EPO or darbepoetin, with ESAs achieving 40-60% erythroid response rates when baseline EPO level is <200-500 U/L and transfusion requirements are low or absent 7, 8, 13.
For higher-risk MDS, hypomethylating agents (HMAs) such as azacitidine are the first-line reference treatment, with azacitidine extending survival by up to 74% despite modest complete response rates 9.

Allo-SCT Eligibility

Evaluate for allo-SCT eligibility at diagnosis, as this is the only potentially curative treatment, with HLA-identical siblings or matched unrelated donors preferred 7, 13, 10.

Response Assessment

Monitor treatment effectiveness using standardized criteria, including complete blood counts, hematologic improvement, complete remission, and partial remission 12.

Iron Overload Management

Iron chelation therapy should be considered if transfusion-dependent, as iron overload increases infection-related mortality 7, 13, 14.

Clinical Trials and Supportive Care

Consider clinical trial enrollment if available, and provide supportive care alone for very frail patients 7, 8, 9, 10.

Treatment of Myelodysplastic Syndrome (MDS) with Trisomy 8

Risk Stratification and Treatment Approach

The International Prognostic Scoring System (IPSS)-R classification is essential for determining the treatment approach, stratifying patients into lower-risk versus higher-risk categories, according to the National Comprehensive Cancer Network (NCCN) 15
Trisomy 8 is classified as an intermediate-risk cytogenetic abnormality in the IPSS-R scoring system, as stated by the European Society for Medical Oncology (ESMO) 16

Lower-Risk MDS with Trisomy 8

ATG is most effective in relatively young patients (<65 years) with low-risk MDS, transfusion history <2 years, normal karyotype or trisomy 8, no excess blasts, and possibly those with thrombocytopenia in addition to anemia, as reported by the European Society for Medical Oncology (ESMO) 17
Erythropoiesis-stimulating agents (ESAs) such as recombinant erythropoietin or darbepoetin achieve 40-60% erythroid response rates when baseline EPO level is <200-500 U/L and transfusion requirements are low, according to the National Comprehensive Cancer Network (NCCN) 15

Higher-Risk MDS with Trisomy 8

Azacitidine 75 mg/m² subcutaneously for 7 consecutive days every 28 days is the first-line reference treatment for higher-risk MDS, including those with trisomy 8, as recommended by the European Society for Medical Oncology (ESMO) 16
At least six cycles of azacitidine are required before assessing response, as most patients only respond after several courses, according to the European Society for Medical Oncology (ESMO) 16
Allogeneic HSCT should be evaluated at diagnosis for all higher-risk patients, as it represents the only potentially curative treatment, as stated by the European Society for Medical Oncology (ESMO) 16

Supportive Care

Iron chelation therapy should be initiated when transfusion-dependent, as iron overload increases infection-related mortality, according to the National Comprehensive Cancer Network (NCCN) 18
Monitor serum ferritin levels with goal <1000 mcg/L, as recommended by the National Comprehensive Cancer Network (NCCN) 18

Myelodysplastic Syndrome (MDS) Management Guidelines

1. Risk Stratification

All patients should be classified with the Revised International Prognostic Scoring System (IPSS‑R), which incorporates cytogenetics, bone‑marrow blast percentage, hemoglobin, platelet count, and absolute neutrophil count to assign one of five risk groups (very low, low, intermediate, high, very high). 19 – NCCN guideline.
Median overall survival (OS) estimates by IPSS‑R range from approximately 8.8 years for very‑low‑risk disease to 0.8 years for very‑high‑risk disease. 20 – International consensus (2021).
Patients classified as IPSS‑R intermediate may be managed as lower‑ or higher‑risk based on age, performance status, serum ferritin, lactate dehydrogenase, severity of cytopenias, and early treatment response. [21][22]23 – NCCN guideline.
Molecular profiling adds prognostic information: TP53 mutations in del(5q) MDS and SF3B1 mutations in patients with <5 % blasts are clinically relevant. 19 – International consensus (2021).
TP53‑mutated MDS predicts poor response to lenalidomide and shorter OS. 22 – NCCN guideline.

2. Lower‑Risk MDS (IPSS‑R Very Low, Low, Intermediate)

Therapeutic Goal

Aim for hematologic improvement—relief of symptomatic cytopenias, enhanced quality of life, and reduced transfusion requirements—rather than disease modification. [22][23] – NCCN guideline.

Anemia Management

For symptomatic anemia with serum erythropoietin ≤ 500 mU/mL, initiate erythropoiesis‑stimulating agents (ESAs) such as recombinant erythropoietin or darbepoetin alfa, with or without granulocyte‑colony stimulating factor (G‑CSF). 23 – NCCN guideline.
ESAs achieve erythroid responses in 40‑60 % of patients when baseline EPO is low (< 200‑500 U/L) and transfusion need is modest (< 2 units/month). [22][23] – NCCN guideline.

del(5q)‑Specific Therapy

Isolated del(5q) MDS with symptomatic anemia should be treated with lenalidomide 10 mg daily for 21 days of a 28‑day cycle. 23 – NCCN guideline.
Prior to lenalidomide, test for TP53 mutations; presence of TP53 alteration predicts reduced response or early relapse and lenalidomide should be avoided as primary therapy in this setting. 22 – NCCN guideline.

Immunosuppressive Therapy

Equine anti‑thymocyte globulin (ATG) ± cyclosporine A is recommended for relatively young patients (≤ 60 years) with ≤ 5 % marrow blasts, hypocellular marrow, HLA‑DR15 positivity, PNH‑clone positivity, or STAT‑3 mutant cytotoxic T‑cell clones. 23 – NCCN guideline.

Supportive Care

Red blood cell transfusions should be given to maintain hemoglobin > 8‑10 g/dL according to symptoms. 23 – NCCN guideline.

3. Higher‑Risk MDS (IPSS‑R Intermediate, High, Very High)

Therapeutic Goal

Objective is disease‑modifying: delay progression to acute myeloid leukemia (AML) and prolong overall survival, targeting complete remission (CR), partial remission (PR), or hematologic improvement (HI). [22][20]24 – NCCN & International consensus (2021).

First‑Line Hypomethylating Agents

Azacitidine 75 mg/m² subcutaneously for 7 consecutive days every 28 days is the reference first‑line regimen for higher‑risk patients not immediately eligible for transplant. [19][20]24 – NCCN guideline.
An alternative “5‑2‑2” schedule (5 days on, 2 days off, 2 days on) is acceptable for logistical reasons. [20][24] – NCCN guideline.
A minimum of six azacitidine cycles should be completed before response assessment, as most responses occur after several courses. [19][20]24 – NCCN guideline.

Allogeneic Stem Cell Transplantation (allo‑SCT)

Allo‑SCT is the only potentially curative option and should be evaluated at diagnosis for all higher‑risk patients ≤ 70 years (or fit patients > 70 years) who have an HLA‑identical sibling or a matched unrelated donor. [19][20]24 – NCCN guideline.
Administering 2‑6 cycles of azacitidine before transplant can reduce blast burden and provide time to secure a donor. [20][24] – NCCN guideline.

Intensive AML‑Like Chemotherapy

Reserved for fit patients < 70 years with favorable cytogenetics (e.g., normal karyotype), marrow blasts > 10 %, and when used as a bridge to allo‑SCT. [20][24] – NCCN guideline.

Management of Very Frail Patients

Patients deemed very frail should receive best supportive care only (transfusions, antibiotics, growth factors) rather than disease‑modifying therapy. [20][24] – NCCN guideline.

4. Response Assessment

Response is evaluated using the International Working Group (IWG) 2006 criteria, which define CR, PR, and HI. [22][20]24 – IWG guideline.
Achieving hematologic improvement is associated with longer survival compared with supportive care alone. [20][24] – International consensus (2021).

5. Patient‑Specific Factors

Age, performance status, and comorbidities are critical determinants of treatment tolerance and should guide therapy selection. [25][22]23 – American Society of Hematology (ASH) guideline.